Fleiss P M, Richwald G A, Gordon J, Stern M, Frantz M, Devlin R G
Br J Clin Pharmacol. 1985 Apr;19(4):509-11. doi: 10.1111/j.1365-2125.1985.tb02677.x.
Serum and milk concentrations of aztreonam were studied in 12 lactating, healthy subjects over the 8 h period after the administration of a single intramuscular or intravenous 1 g dose. Milk concentrations of aztreonam were found to be much lower than serum concentrations at all time points after both routes of injection. Peak milk concentrations of aztreonam averaged less than 1% of peak serum concentrations. Times to peak concentrations averaged 6 and 10 times longer in milk than in serum after intramuscular and intravenous injections, respectively. The low milk levels, as well as the previously determined poor oral absorption of aztreonam, suggest a low risk of untoward effects in the nursing infant.
在12名哺乳期健康受试者单次肌内或静脉注射1g剂量氨曲南后的8小时内，对其血清和乳汁中氨曲南的浓度进行了研究。发现在两种注射途径后的所有时间点，乳汁中氨曲南的浓度均远低于血清浓度。氨曲南的乳汁峰值浓度平均不到血清峰值浓度的1%。肌内注射和静脉注射后，乳汁中达到峰值浓度的时间分别平均比血清中长6倍和10倍。乳汁中氨曲南水平较低，以及先前确定的氨曲南口服吸收较差，提示哺乳期婴儿出现不良反应的风险较低。
